| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The exact molecular target of Imidocarb is not fully elucidated, but it is believed to interfere with the metabolism of protozoan parasites. One proposed mechanism involves disrupting the production or utilization of polyamines within the parasite, which are essential for their growth and replication. Other suggested actions include inhibiting the binding of key biomolecules like AMP and ATP, as well as interfering with nucleic acid synthesis in the parasite.
|
|---|---|
| ln Vitro |
Imidocarb demonstrates potent in vitro activity against the parasite Babesia bovis, with an IC50 of 87 microg/mL. This quantitative measure confirms its direct antiparasitic efficacy against a key pathogen responsible for babesiosis in livestock. This activity has been validated through standardized assays, establishing Imidocarb as a reference compound for antiprotozoal drug screening.
|
| ln Vivo |
Imidocarb dipropionate is administered by subcutaneous or intramuscular injection to horses (3.4 mg/kg bw) and cattle (2.I mg/kg bw). In horses, up to 4 doses may be given at 72-hour intervals. A second dose may be given 2 weeks after the first. Imidocarb dipropionate is also used in sheep (1. 2mg/kg bw) for the treatment of babesiosis and anaplasmosis. The acute oral The acute oral LD50 value of Imidocarb dipropionate is in the range of 646 to 723 mg/kg bw in mice. The acute oral LD50 value of Imidocarb is in the range of 454 to 1251 mg/kg bw in rats.
In vivo, Imidocarb is administered to animals for the treatment and prevention of protozoal diseases. For instance, it is given to horses at 3.4 mg/kg body weight and to cattle at 2.1 mg/kg body weight via subcutaneous or intramuscular injection. It exhibits activity against various Babesia species, Theileria, and Anaplasma, providing both therapeutic and prophylactic protection. The compound is known to have a long duration of action in the body. |
| Enzyme Assay |
A typical antiparasitic drug susceptibility assay: B. bovis parasites are cultured in bovine red blood cells in a 96-well plate. Imidocarb is serially diluted in culture medium and added to the parasite culture. After 96 hours of incubation at 37degC in a 5% CO2 incubator, parasite growth is assessed by microscopic examination of Giemsa-stained blood smears or by measuring fluorescence using a DNA-binding dye like SYBR Green I. The 50% inhibitory concentration (IC50) is calculated from the dose-response curve.
|
| Cell Assay |
No specific cellular pharmacology protocols are applicable, as Imidocarb is directly active against blood-borne parasites rather than adherent mammalian cells. For parasite cultivation, B. bovis-infected erythrocytes are maintained in culture medium consisting of RPMI-1640 supplemented with 40% bovine serum at 37degC under an atmosphere of 5% O2, 5% CO2, and 90% N2. Compound efficacy is typically determined using microscopic parasite count or nucleic acid staining-based assays.
|
| Animal Protocol |
A standard in vivo efficacy model: Cattle (approx. 200-250 kg body weight) naturally infected or experimentally challenged with B. bovis are treated with Imidocarb dipropionate at a dose of 2.1 mg/kg by subcutaneous injection. Clinical signs (fever, anemia, hemoglobinuria) are monitored daily for 14-21 days post-treatment. Parasitemia levels are determined by microscopic examination of Giemsa-stained blood smears. The compound is also used prophylactically at similar doses.
|
| ADME/Pharmacokinetics |
The primary active form and detailed PK parameters of Imidocarb are not fully described in the available literature. As a veterinary drug, it is known to be administered as an injectable solution of its dipropionate or dihydrochloride salts. The compound is designed for intramuscular or subcutaneous injection and is known to have a long duration of action in treated animals, providing both therapeutic and prolonged prophylactic effects against tick-borne diseases.
|
| Toxicity/Toxicokinetics |
Imidocarb is classified as a toxic agent, but its detailed safety profile is not provided. For veterinary use, care should be taken to avoid injection site reactions and systemic toxicity. Imidocarb is toxic to humans and should be handled with appropriate safety precautions in a laboratory setting. The LD50 in various animal species has not been reported in the summarized literature.
|
| References | |
| Additional Infomation |
Imidocarb is an antiprotozoal drug. Imidocarb is a urea derivative used in veterinary medicine as an antiprotozoal drug to treat Babesia and other parasitic infections. It is one of the antiprotozoal drugs specifically used to treat Babesia infection in livestock. Toxicity has been reported. See also: Imidocarb dipropionate (its active ingredient); Imidocarb hydrochloride (its active ingredient).
Imidocarb is a well-established veterinary drug, available as an injection in various countries. It is used for the treatment of babesiosis and anaplasmosis, which are economically important tick-borne diseases of livestock. The product is for research and veterinary use only and is not intended for human applications. Additional research suggests a role in optimizing PCR processes, possibly due to its ability to induce chemotactic activity. Each product in one row, fields tab-separated. |
| Molecular Formula |
C19H20N6O
|
|---|---|
| Molecular Weight |
348.40
|
| Exact Mass |
348.17
|
| CAS # |
27885-92-3
|
| Related CAS # |
Imidocarb dipropionate;55750-06-6;Imidocarb dihydrochloride monohydrate;Imidocarb (Standard);27885-92-3
|
| PubChem CID |
21389
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
677.1ºC at 760 mmHg
|
| Flash Point |
363.3ºC
|
| Vapour Pressure |
2.94E-19mmHg at 25°C
|
| Index of Refraction |
1.724
|
| LogP |
-0.45
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
526
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(NC1=CC=CC(C2=NCCN2)=C1)NC3=CC=CC(C4=NCCN4)=C3
|
| InChi Key |
SCEVFJUWLLRELN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H20N6O/c26-19(24-15-5-1-3-13(11-15)17-20-7-8-21-17)25-16-6-2-4-14(12-16)18-22-9-10-23-18/h1-6,11-12H,7-10H2,(H,20,21)(H,22,23)(H2,24,25,26)
|
| Chemical Name |
1,3-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]urea
|
| Synonyms |
Diimidazole; Diimidazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~71.76 mM; with ultrasonication (<60°C))
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.18 mM)(saturation unknown) in 10% DMSO 40% PEG300 5% Tween-80 45% Saline (add these co-solvents sequentially from left to right, and one by one),clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 400 μL PEG300, mix well; then add 50 μL Tween-80 to the above system, mix well; then continue to add 450 μL of normal saline to make up to 1 mL. Preparation of normal saline: Dissolve 0.9 g of sodium chloride in ddH₂O and make up to 100 mL to obtain a clear and transparent normal saline solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.18 mM)(saturation unknown) in 10% DMSO 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one),clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 900 μL of 20% SBE-β-CD saline solution and mix well. 2 g SBE-β-CD (sulfobutyl ether β-cyclodextrin) powder is diluted to 10 mL of saline and completely dissolved until clear and transparent. Solubility in Formulation 3: ≥ 2.5 mg/mL (7.18 mM)(saturation unknown) in 10% DMSO 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one),clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 900 μL corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8703 mL | 14.3513 mL | 28.7026 mL | |
| 5 mM | 0.5741 mL | 2.8703 mL | 5.7405 mL | |
| 10 mM | 0.2870 mL | 1.4351 mL | 2.8703 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
